Cellular senescence is a tumour-suppressor mechanism that is triggered by cancer-initiating or promoting events in mammalian cells. The molecular underpinnings for this stable arrest involve transcriptional repression of proliferation-promoting genes regulated by the retinoblastoma (RB1)/E2F repressor complex. Here, we demonstrate that AGO2, RB1 and microRNAs (miRNAs), as exemplified here by let-7, physically and functionally interact to repress RB1/E2F-target genes in senescence, a process that we call senescence-associated transcriptional gene silencing (SA-TGS). Herein, AGO2 acts as the effector protein for let-7-directed implementation of silent-state chromatin modifications at target promoters, and inhibition of the let-7/AGO2 effector complex perturbs the timely execution of senescence. Thus, we identify cellular senescence as the an endogenous signal of miRNA/AGO2-mediated TGS in human cells. Our results suggest that miRNA/AGO2-mediated SA-TGS may contribute to tumour suppression by stably repressing proliferation-promoting genes in premalignant cancer cells.
Cellular senescence represents a robust and essentially irreversible tumour-suppressive barrier that cells must overcome to develop into a full-blown malignancy 1 . Previous studies have proposed that the irreversibility of the senescence arrest is tightly associated with the senescent cells' particular chromatin architecture, which is epitomized by the appearance of so-called senescence-associated heterochromatin foci (SAHFs; refs 2,3). SAHFs are a hallmark of senescent cells that contain several common markers of transcriptionally repressed heterochromatin and were hypothesized to silence genes important for cell proliferation, in particular those regulated by the E2F/RB1 repressor complex (for example cyclin A2 (CCNA2), cyclin E (CCNE) or proliferating cell nuclear antigen (PCNA); ref. 2). However, whether or not SAHFs really contain E2F-target genes and how the senescence-associated inactive chromatin state at E2F-target genes is implemented and maintained remains unclear. Recent studies in model organisms have provided a link between argonaute (AGO) proteins, short interfering (si)RNAguided heterochromatin formation and transcriptional gene silencing (TGS; ref. 4) . In humans, there are four AGO proteins (AGO1-4, also known as eukaryotic translation initiation factor 2C, 1-4 (EIF2C1-4)), and AGO1 and 2 have been previously implicated in TGS induced by exogenous siRNAs and microRNAs (miRNAs) directed against gene promoter transcripts through promotion of changes in histone To determine, in an unbiased manner, which genes might be under the control of AGO proteins, we carried out genome-wide promoter profiling in senescent and presenescent control WI38 primary fibroblasts applying 'ChIP (chromatin immunoprecipitation)-on-chip' technology using an anti-pan-AGO antibody. The enrichment value for each promoter was determined (Methods) and yielded 4,516 potential AGO-promoter binding sites in senescent cells versus 2,619 in presenescent cells. Of these binding sites, 702 were in common between the two conditions; however, the false-discovery rate for AGO-binding sites in senescent cells was several-fold lower than in control cells, indicating an enrichment for AGO proteins at the respective promoters Table S1 ). To probe a potential link between AGO proteins and E2F-target promoters, we inspected how many of the E2F-regulated promoters were AGO bound. This analysis revealed, that of the top 577 E2F-responsive promoters known at present [8] [9] [10] [11] , 320 (that is 55.5%) were occupied by AGO proteins in senescent cells, as opposed to only 77 (that is 13.3%) in control cells (Fig. 1b) . We then correlated AGO-promoter occupancy of E2F-target genes with the comparative expression profile of these genes in senescent versus presenescent control cells using microarray-based transcriptome data. We found that, of the 320 AGO-bound E2F-target genes, 150 (that is ∼46.5%) were down-and 65 (that is ∼20.6%) were upregulated ( Fig. 1c and Supplementary  Table S1 ). Functional annotation of the 150 downregulated E2F-target genes showed a clear enrichment in genes involved in cell-cycle control ( Supplementary Fig. S2a and Table S2 ), whereas no significant enrichment was found for upregulated E2F-target genes (data not shown). Together, these results suggest that AGO proteins may be involved in senescence-associated repression of E2F-target genes.
Exogenous miRNAs with sequence complementarity to promoter regions were shown to induce AGO-mediated TGS by implementing a transcriptionally repressive chromatin environment 7 . This led us to investigate whether miRNAs might be involved in AGO-mediated repression of E2F-target genes in senescence. To obtain a detailed picture of AGO-immunoprecipitating miRNAs (RIPs) in senescent cells, we used next-generation sequencing (NGS). Importantly, we included histone H3 dimethylated on lysine 9 (H3K9me2) in this analysis to assign potential AGO2-interacting miRNAs to a repressive chromatin state and unfractionated, cellular RNA from senescent cells for normalization ( Supplementary Fig. S2b ). Small RNA sequences were determined by NGS, producing between 3.2 and 4.5 million 33-nucleotide sequences for the three samples (Supplementary Table S3 ). To search for previously known miRNAs within these results, we ran a string-matching algorithm (allowing one mismatch) to count the number of sequences aligning with human mature miRNAs. Of the known 847 human mature and mature-star miRNAs annotated in release 12.0 of miRBase, we identified a total of 451 unique miRNAs in unfractionated cellular RNA, 377 in RIP-AGO and 237 in RIP-H3K9me2 of senescent cells (Supplementary Table S4 ). After adjusting for sequencing depth by converting to logarithmic counts per million sequence reads (log cpm), we computed the degree of association (Pearson coefficient, r; coefficient of determination, r 2 ) between miRNA expression in unfractionated, cellular RNA and RIP-associated miRNAs and between AGO-and H3K9me2-associated miRNAs (Fig. 1d-f) . We found that the degree of association between miRNA expression in unfractionated, cellular RNA and AGO-associated miRNAs is high (r = 0.862; P < 0.000001; Fig. 1d ), whereas the degree of association between miRNA expression in unfractionated, cellular RNA and H3K9me2-associated miRNAs is only moderate (r = 0.686; P < 0.000001; Fig. 1e ). Remarkably, however, the degree of association between AGO-and H3K9me2-associated miRNAs is high (r = 0.888; P < 0.000001; Fig. 1f) , thus there exists a strong positive correlation between AGO-bound and heterochromatin-bound miRNAs in senescent cells.
AGO2 accumulates in the nucleus of senescent cells to target repressed E2F-responsive promoters
Having established a link between AGO proteins and promoters of repressed E2F-target genes on the one hand as well as AGO-bound miRNAs and a repressive chromatin state on the other hand, we Western-blot analysis of cytosolic and nuclear fractions from RAS V12 -induced senescent (S) and presenescent, empty vector control (C) WI38 fibroblasts using anti-AGO2, anti-lamin B and anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase) specific antibodies. Lamin B and GAPDH detection serve as positive controls for nuclear and cytosolic fractions; WCL, whole-cell lysate. (b) Localization of AGO2 in detergent-pre-extracted presenescent, control (C) and senescent (S) cells as determined by indirect immunofluorescence microscopy. 4,6-diamidino-2-phenylindole (DAPI) was used to counterstain nuclear DNA; scale bar, 10 µm. (c,d) Co-localization of AGO2 and macroH2A in nuclei of melanocytic nevus (c) and in cytosol of melanoma (d) as determined by indirect immunofluorescence; scale bar, 20 µm. (e) Global AGO2 enrichment in heterochromatin of senescent cells as detected by histone-association assay. Presenescent, control (C) and senescent (S) cells were fixed by paraformaldehyde, sonicated and lysed. Euchromatin-and heterochromatin-bound AGO2 was identified by co-immunoprecipitation (Co-IP) using anti-histone H3K9ac (euchromatin), H3K27me3, H3K9me2 (heterochromatin) and IgG control antibodies. Immunoprecipitates were Western blotted with anti-AGO2 and anti-histone H3 antibodies. Ratios were calculated densitometrically. (f) AGO2 and histone modification profiling of E2F-responsive promoters. qChIP was carried out in presenescent, empty vector control (C) and RAS V12 -induced senescent (S) cells using anti-AGO2, anti-H3K27me3, anti-H3K9me2, anti-H3K4me3 and IgG control antibodies followed by qPCR of CDC2, CDCA8, PCNA and CCNA2 promoters. Data are means ± s.d.; n = 3; P < 0.05. Experiments were carried out in quadruplicate. Uncropped images of blots are shown in Supplementary  Fig. S9 .
were then interested in whether a specific AGO-miRNA effector complex is involved in SA-TGS of E2F-target genes. There are four AGO proteins (AGO1-4) in humans. AGO2 was recently shown to undergo nucleo-cytoplasmic shuttling 12 and to be differentially expressed in human cancers [13] [14] [15] . Therefore, we focused on AGO2 in the further study. First, we sought to determine whether AGO2 may accumulate in the nucleus of cells undergoing senescence using an anti-AGO2 specific monoclonal antibody ( Supplementary Fig. S2c ). Senescence was induced either by retroviral introduction of oncogenic RAS V12 into WI38 primary human diploid fibroblasts, by treatment of MCF-7 breast cancer cells with senescence-inducing concentrations of doxorubicin or by re-expression of RB1 in RB1-inducible Saos-2 (RB1-negative) cells. Biochemical fractionation (Fig. 2a and Supplementary  Fig. S2d ) and indirect immunofluorescence studies ( Fig. 2b and Supplementary Fig. S2e ,f) revealed that AGO2 accumulates in the nucleus of senescent cells when compared with presenescent control cells, although the overall protein levels remain largely unchanged. To extend the physiological significance of senescence-associated nuclear accumulation of AGO2 from cell culture to human tissue samples, we analysed localization of AGO2 in melanocytic nevi and melanomas by indirect immunofluorescence. Nevi are archetypes of benign tumours that frequently harbour oncogenic mutations and are highly enriched in senescent melanocytes, whereas melanomas are malignant tumours essentially devoid of senescent melanocytes [16] [17] [18] . Strikingly, we observed a pronounced nuclear enrichment of AGO2 in senescent melanocytic nevi, as shown by its co-localization with the senescence marker macroH2A (refs 19,20; Fig. 2c and Supplementary Fig. S3a-d) . Conversely, in melanomas AGO2 was essentially excluded from melanocytic nuclei and predominantly localized to the cytosol ( Fig. 2d and Supplementary Fig. S3e-g ). Next, we quantitatively assessed AGO2's partitioning between heterochromatin and euchromatin using a histone association assay 21 . We established that, in senescent cells, AGO2 predominantly co-precipitates with facultative heterochromatin 
Control shRNA markers histone H3 trimethylated on lysine 27 (H3K27me3) and H3K9me2 when compared with presenescent control cells (Fig. 2e) . By contrast, a comparable amount of AGO2 co-precipitated with the euchromatin marker histone H3 acetylated at lysine 9 (H3K9ac) in both cell states (Fig. 2e) . We conclude that AGO2 accumulates in the nucleus of senescent cells, where it shows an increased affinity to inactive chromatin when compared with presenescent cells.
To validate AGO2-bound E2F-target promoters as revealed by ChIP-on-chip, we used qChIP (ChIP quantified by real-time PCR) for a selected number of target genes. Simultaneously, we also examined histone modifications at the respective promoters and the gene-expression statuses. We found that AGO2 levels were elevated ∼2-4-fold on selected E2F-target promoters of CDC2 (also known as CDK1, cyclin-dependent kinase 1), CDCA8 (cell division cycle associated 8), PCNA and CCNA2 (Fig. 2f) Fig. S4a ) in senescent cells when compared with presenescent cells. The elevated physical presence of AGO2 at the respective promoters was accompanied by a substantial increase in the negative methyl histone marks H3K27me3 (∼3-6-fold) and H3K9me2 (∼2-4-fold) and by a decrease (∼2-6-fold) in the positive methyl histone mark histone H3 trimethylated on lysine 4 (H3K4me3; Fig. 2f ) and paralleled by a decrease (∼2-5-fold) in expression of the respective genes ( Supplementary Fig. S4b ). Importantly, in senescent cells silenced for AGO2 expression we detected a greatly diminished presence of AGO2 at investigated promoters, thus underscoring AGO2 specificity ( Supplementary Fig. S4c,d ). Together, these results provide strong evidence for an enrichment of AGO2 at E2F-target promoters in senescent cells. Moreover, they reveal that the repressive histone modification marks H3K27me3 and H3K9me2 coincide with the presence of AGO2 at E2F-regulated cell-cycle genes in senescence arrest, thus hinting at an active contribution of AGO2 in senescence-associated repression of E2F-target genes.
Physical and functional interaction between AGO2 and RB1 in the regulation of E2F-target genes in senescent cells
The RB1 protein functions as a repressor of E2F-target genes in senescent cells supposedly by nucleating heterochromatin formation at respective promoters 2 , at least partly through recruitment of histone deacetylase 1 (HDAC1) or histone methyl-transferase SUV39H (refs 22-25) . We therefore considered whether AGO2 might be involved in RB1-mediated repression in senescence. To test this possibility, we first carried out co-immunoprecipitation experiments between endogenous AGO2, RB1 and HDAC1 in cellular lysates prepared from RAS V12 -induced senescent fibroblasts. As shown in Fig. 3a, HDAC1 and AGO2 co-immunoprecipitated with each other. Moreover, both HDAC1 and AGO2 efficiently co-immunoprecipitated RB1. Similar results were obtained in Saos-2 cells undergoing RB1-induced senescence (Fig. 3b) . Consistent with the physical interaction between AGO2 and RB1, AGO2 showed partial co-localization with SAHFs at their periphery, a staining pattern that was similar for the heterochromatin marker H3K27me3 (Supplementary Fig. S5a ) and RB1 (ref. 2) and is thus congruent with the peripheral SAHF localization of E2F-target genes 3 . Next, we investigated whether AGO2 could act as a co-repressor with RB1 by carrying out promoter-reporter assays using the natural E2F-responsive CCNE promoter 26 . Expression of RB1 repressed E2F-mediated transactivation of the promoter by 79% whereas increasing amounts of AGO2 led to a 37-47% repression (Fig. 3c , columns 2-5). A co-repressive effect was observed when both AGO2 and RB1 were present simultaneously (Fig. 3c , columns 6 and 7) and this effect was further enhanced in the presence of HDAC1 (data not shown). Co-repression between AGO2 and RB1 was specific for AGO2 as its paralogue AGO1 had no effect (Fig. 3c, columns  8 and 9 ). By contrast, RB1 and AGO2 did not affect a version of the cyclin E promoter in which the E2F1-recognition sites were eliminated by mutation (Fig. 3d) . The repressive function of AGO2 on expression of endogenous E2F-target genes was then verified using quantitative real-time PCR (qrtPCR) on total RNA isolated from RAS V12 -induced senescent fibroblasts silenced for AGO2 expression by RNA interference. RAS V12 -induced senescent fibroblasts treated with AGO2 siRNA, but not with AGO1 siRNA, showed derepression of E2F-target genes ( Fig. 3e and Supplementary Fig. S5b ) and this was positively correlated with a decreased presence of H3K27me3 and RB1 at target promoters (Fig. 3f) . Combined, these results show that AGO2 and RB1 cooperate in the transcriptional repression of E2F-responsive promoters. Interestingly, AGO2 recruitment to E2F-target promoters seems to be largely independent from RB1, as siRNA-mediated depletion of RB1 only mildly impacts the physical presence of AGO2 at tested promoters ( Fig. 3g-i ).
AGO2 deficiency regulates the onset of senescence
Given the repressive function of AGO2 on E2F-target genes in senescence, we tested whether AGO2 plays an active role in the establishment of the senescent phenotype. To start to address this question, we first overexpressed RAS V12 either in fibroblasts expressing control short hairpin RNA, in fibroblasts in which AGO2 expression was stably silenced by either of two distinct short hairpin RNAs (AGO2 shRNA 1 and 2) or in fibroblasts overexpressing viral oncogene HPV16E7, the latter serving as a positive control for senescence delay by interfering with the RB1 pathway. Cells expressing control shRNA and RAS V12 ceased proliferation and senesced within 7 days. By contrast, RB1-and AGO2-deficient RAS V12 cells had a slightly postponed senescence onset by ∼2.5-3 population doublings but were unable to completely bypass senescence (Fig. 4a,b) . Consistently, in AGO2-deficient RAS V12 cells the percentage of 5-ethynyl-2 -deoxyuridine (EdU)-incorporating cells increased and the fraction of SAHF-positive cells decreased transiently when compared with control cells expressing RAS V12 and control shRNA (Fig. 4c,d and Supplementary Fig. S6 ). Similar results were obtained in cells treated with AGO2 siRNA molecules (see Fig. 7a below) . on CDCA8 and CDC2 promoters was determined by combined qChIP-ChOP assay. Presenescent WI38 fibroblasts were transfected with 100 nM biotin-labelled let-7f, control miRNA (siC) or let-7 followed by successive rounds of control-IgG-ChIP or AGO2-ChIP and streptavidin-affinity (SA) precipitation. Streptavidin-affinity chromatin precipitates were analysed by qPCR with primers detecting E2F-responsive promoters CDCA8 and CDC2. Data are means ± s.d.; n = 4; P < 0.001. Experiments were carried out in duplicate. (f) Presence of let-7 at target promoters is AGO2 dependent. Presenescent WI38 were co-transfected with AGO2 siRNA or siC (100 nM) and biotin-labelled let-7f (100 nM) followed by streptavidin-affinity precipitation. Data are means ± s.d.; n = 3; P < 0.05. Experiments were carried out in duplicate. To further corroborate the functional requirement for AGO2 in cellular senescence, we investigated its role in replicative senescence. Accordingly, we silenced AGO2 expression in medium-passage fibroblasts with shRNAs and determined their replicative potential using doublings (Fig. 4e) . In line with this finding, the fraction of AGO2-deficient cells incorporating EdU increased and senescence-associated beta-galactosidase (SA-β-Gal) activity decreased transiently when compared with shC control cells (Fig. 4f,g ). Next, we overexpressed AGO2 in early-passage WI38 fibroblasts. Strikingly, AGO2-overexpressing cells induced an abrupt proliferative arrest (Fig. 5a ) with features of senescence as shown by a decrease in the number of cells incorporating EdU (Fig. 5b) and an increase in the percentage of SAHF-positive cells (Fig. 5c-e) . Altogether, these data indicate that AGO2 actively contributes to the proper execution of the senescence response.
AGO2-miRNA complexes are involved in SA-TGS of E2F-target genes
We hypothesized that AGO-bound miRNAs with sequence complementarity to promoter regions may induce AGO-mediated SA-TGS by implementing a transcriptionally repressive chromatin environment. On closer inspection of all detected miRNAs, we found that the top ten AGO2-interacting miRNAs were identical to the top ten H3K9me2 heterochromatin-interacting miRNAs and were all members of the let-7 family, with let-7a and let-7f having the highest normalized sequence counts (cpm; Supplementary Table S5 ). The interaction between either H3K9me2 or AGO2 and let-7f was confirmed by RNA immunoprecipitation combined with small RNA complementary DNA (srcDNA) cloning and sequencing 27 in senescent cells (Fig. 6a) . Of note, pre-miRlet-7f2 shows the strongest upregulation among the let-7 family members in senescent cells when compared with control cells (Supplementary Fig. S7a) . In the further analysis we therefore focused our attention on let-7f function in SA-TGS. To assess whether let-7f directs TGS in senescent cells, we carried out a bioinformatic search for potential binding sites in AGO2-repressed E2F-target promoters using RNAhybrid 28 . We found two imperfectly matched, putative let-7f-target sites showing very low minimal free energy (mfe) values of hybridization, one in the antisense direction of the CDC2 promoter at position −388 to −410 (mfe = 19.9 kcal mol −1 ) and the other in the sense direction of the CDCA8 promoter at position −220 to −241 (mfe = 29.4 kcal mol −1 ) relative to the respective transcriptional start sites (TSSs; Fig. 6b ).
To elucidate whether let-7 and the putative let-7-binding site in the E2F-responsive CDC2 promoter 29 are involved in RB1/AGO2-mediated transcriptional repression, we initially carried out promoter-reporter assays using a wild-type version of the CDC2 promoter or a derivative thereof in which the putative let-7-binding site was mutated ( Supplementary Fig. S7b-d) . Expression of RB1 repressed both the wild-type and let-7-mutated promoter (∼1.8 versus ∼1.4-fold). When we co-transfected cells with either RB1/let-7, RB1/AGO2 or RB1/AGO2/let-7 and the respective promoter-reporter construct, we observed an increasing co-repressive effect between let-7, AGO2 and RB1 only for the wild-type (RB1:let-7, ∼3-fold; RB1:AGO2, ∼4-fold; RB1:AGO2:let-7, ∼5-fold) and not the let-7-mutated promoter-reporter construct (RB1:let-7, ∼1.9-fold; RB1:AGO2, ∼1.9-fold; RB1:AGO2:let-7, ∼2.2-fold). These data indicate that let-7, AGO2 and RB1 cooperate in the repression of the E2F-responsive CDC2 promoter and that the let-7 site at position −388 to −410 is important for optimal repression.
On the basis of the promoter-reporter data, we then assessed the susceptibility of CDCA8 and CDC2 genes to miRNA-mediated TGS by transiently transfecting let-7f or control miRNA into earlypassage WI38 human fibroblasts and monitoring CDCA8 and CDC2 transcript levels either by nuclear-run-on transcription assay or qrtPCR. Transcript abundance was significantly reduced for the two genes in the presence of let-7f (Fig. 6c) or pre-miR-let-7f ( Supplementary Fig. S8a ) in both assays. The nuclear-run-on data, however, indicated that let-7f-induced gene silencing occurs directly at the transcriptional level. To examine whether silencing leads to recruitment of AGO2 and changes in histone marks at the respective promoters, we carried out qChIP of let-7f-and pre-miR-let-7f-treated cells. We observed a pronounced let-7f-dependent enrichment of AGO2 and H3K27me3 at the CDCA8 and CDC2 promoters ( Fig. 6d and Supplementary Fig. S8b ). Importantly, AGO2 and let-7f were simultaneously present at the CDCA8 and CDC2 promoters as shown by a dual-pulldown assay (qChIP-ChOP, chromatin-oligo-affinity precipitation 30 ; Fig. 6e ). Using this assay, we also identified ORC6L as an AGO2/miR-185-bound E2F-response gene (Supplementary . We favour a model in which the complex is guided by the miRNA (red) to the respective target promoter(s), where it associates with promoter-associated RNA(s) (pRNA) (left), which has/have been shown to be critical for TGS (ref. 30) . Indeed, our preliminary data indicate that RNA Pol II-dependent TSS-proximal pRNAs are produced at E2F targets in proliferating cells, whereas in senescent cells these transcripts become almost extinct. Thus, it remains to be seen whether or not AGO2 slices pRNAs after association with the respective promoters. Alternatively, the complex may directly target complementary target promoter sequences (right). In both cases, the miRNA/AGO2 complex ultimately blocks productive RNA Pol II engagement and cooperates with E2F/RB1 to repress E2F-target promoters through recruitment of (further) co-repressor activities including histone methyl transferases (HMTs) and deacetylases (HDACs) and/or by stabilizing a pre-existing E2F/RB1-associated repressor complex. Targeted promoters are ultimately stably repressed by an inactive chromatin state characterized by methylated lysines 9 and 27 on histone H3 as cells undergo senescence.
Fig. S8c
). The physical interaction between let-7 and the respective promoters was found to be AGO2 dependent, as in AGO2-depleted cells let-7 detectability at the respective promoters was greatly diminished (Fig. 6f) . Moreover, let-7 was undetectable at the E2F-responsive AGO2 target promoter of CDC6, which shows no sequence complementarity to let-7 ( Supplementary Fig. S8d ). Strikingly, introduction of let-7f or pre-miR-let-7f into presenescent WI38 fibroblasts led to proliferation arrest (as did treatment of cells with CDCA8 siRNA) with cellular features reminiscent of senescence, whereas AGO2 siRNA/let-7 treated cells proliferated normally (Fig. 6g,h and Supplementary Fig. S8e-g ). Conversely, senescent fibroblasts treated with a let-7f antagomir showed enhanced proliferative capacity as manifested by an increase in both cell proliferation and positive Ki67 immunostaining (Fig. 7a,b) . However, the observed effects were less prominent than in senescent cells treated with AGO2 siRNA, indicating that AGO2 depletion has a more widespread effect on cell proliferation. Furthermore, let-7f-antagomir-treated senescent cells had decreased amounts (about half) of AGO2 at CDCA8 and CDC2 promoters (Fig. 7c) , whereas mRNA levels were increased (Fig. 7d) . Collectively, these results support the conclusion that let-7f, AGO2 and RB1 cooperate to nucleate a transcriptionally repressive chromatin state at selected target promoters during senescence, thus promoting the proper execution of the senescence response.
DISCUSSION
Several studies have linked synthetic siRNAs and endogenous miRNAs targeted to promoter regions to heterochromatin formation and TGS in human cells; however, an endogenous trigger for this phenomenon has not been identified so far 5 . Moreover, the global association of endogenous RNA interference components with chromatin and their role in TGS has so far not been studied in detail. Here, we report a genome-wide chromatin-binding analysis for endogenous AGO proteins and miRNAs in human cells and provide direct evidence for cellular senescence as a physiological signal for miRNA-mediated TGS to occur. The results of our study strongly suggest that in particular nuclear AGO2 acts as the effector protein for miRNA-guided SA-TGS and cooperates with RB1 in the stable repression of certain E2F-target genes in senescence (Fig. 8) . The roles AGO2 and let-7 (plus other miRNAs) play in SA-TGS are critical for the implementation of inactive chromatin marks at target promoters and may thus play an important role for the timely execution of the senescence arrest, as exemplified here by their ability to repress expression of the CDC2 and CDCA8 oncogenes. These findings, therefore, extend the well-established role of miRNAs and AGO2 in cytosolic post-transcriptional gene silencing to nuclear TGS, although the exact contribution of miRNA-mediated TGS and post-transcriptional gene silencing for senescence remains to be determined.
What might be the underlying mechanism for AGO2/miRNAmediated SA-TGS? Our data imply that miRNA/AGO2 complexes may bring in further co-repressor functions such as HDACs or histone methyl transferases to stably silence gene expression and may constitute an effective roadblock for productive engagement of RNA polymerase II (Pol II) at targeted promoters. Alternatively, and not mutually exclusively, they could also enhance the stability of the RB1-associated repressor complex(es). An important question that needs to be addressed in the future concerns the mechanism by which AGO2/miRNA complexes accumulate in the nucleus of senescent cells. Another important question that awaits answers regards the mechanism by which AGO2/miRNA complexes are tethered to their respective target promoters. In conclusion, we provide strong evidence that nuclear translocation/retention and function of miRNA/AGO2 complexes involved in SA-TGS may represent a decisive parameter for tumour suppression. Further studies are now needed to identify other nuclear AGO/miRNA complexes regulating both E2F-and non-E2F-responsive genes during senescence. 
METHODS

Methods
RAS
V12 and LXSN-HPV16E7 were as reported 31 . MigR and MigR-AGO2 were from A. Tarakhovsky. Lentiviral AGO2 shRNA constructs TRCN0000007864, TRCN00000011203 and shControl SHC002 were from Sigma. Lentiviral infection was carried out by standard procedures. The CDC2 wild-type and mutant promoter constructs were cloned by PCR into pGL3 (Promega). Low-passage, primary human diploid fibroblast strain WI38 and breast cancer cell line MCF-7 were purchased from ATCC. Tetracycline (Tet)-Off RB1-inducible Saos-2 cell line was from L. Zhu 32 . Culturing of cells and infection of primary human diploid fibroblasts strain WI38 by retroviral-mediated gene transfer were carried out at physiological oxygen concentration of 3% as previously described 31 . . Subsequently, drug was washed out and cells were left in fresh medium for 4-5 days, after which they became senescent. RB1-inducible Tet-Off was used to induce senescence in Saos-2 cells. Tet was washed out from the medium and Tet-free fresh medium was added. Senescence of cells was obtained within 4-5 days. Senescence was assessed using several assays as previously published 31, 34 . Briefly, proliferative capacity was determined by growth curves, indirect immunofluorescence using anti-Ki67 antibody staining (Boehringer) or EdU incorporation using Click-iT (Invitrogen) as per the manufacturer's instructions. Cells were also co-stained for SA-β-Gal activity. Subcellular fractionation. Cells were collected and lysed in CSK buffer on ice (0.5 M sucrose; 15 mM Tris at pH 7.5; 60 mM KCl; 0.25 mM EDTA; 0.125 mM EGTA; 0.5 mM spermidine; 0.15 mM spermine; 1 mM dithiothreitol). Subsequently, NP-40 was added to a final concentration of 0.5% and lysates were centrifuged to obtain a cytosolic supernatant and nuclear pellet. Nuclei were further purified by centrifugation at 300g through a 0.88 M sucrose cushion.
Co-immunoprecipitation and Western blotting. Cells were extracted in 300 mM NaCl, 10 mM Tris at pH 8.0, 0.5% NP-40, 1 mM EDTA and protease inhibitors. For immunoprecipitations, equal amounts of lysate were incubated with 1-2 µg of respective antibodies overnight at 4 • C. Precipitates were prepared and analysed by Western blotting according to standard procedures using indicated antibodies at a dilution of 1:1,000. When immunoprecipitation was not carried out, Western blotting of total protein lysates was carried out according to standard procedures.
ChIP and histone association assay. ChIP assay on chromatin from senescent and presenescent, control cells was carried out using 1-2 µg of respective antibodies as described 35 . Calculation of the amount of immunoprecipitated E2F-target promoter DNA relative to that present in total input chromatin was calculated according to ref. 36 . When the histone association assay was carried out, crosslinked cellular lysates were immunoprecipitated with the respective histone antibodies according to ref. 21 . Co-immunoprecipitates were analysed by Western blot using indicated antibodies.
Dual affinity purification (ChIP-ChOP). Presenescent WI38 fibroblasts were transfected in multiple replicates with 100 nM antisense 5 -biotin-tagged miR-let-7f (MWG). Cultures were collected 72 h after transfections and ChIP-ChOP assay was carried out according to ref. 30 with minor modifications.
Nuclear run-on. 50,000 presenescent fibroblasts were transfected with indicated miRNAs. Nuclear run-on was carried out as described in ref. 37 . A dot blot assay of pulled-down RNA was carried out using radiolabelled CYP for normalization and CDC2 and CDCA8 reverse primers as probes and autoradiography for visualization.
Immunofluorescence. Cells were prepared and immunolabelled with primary (1:200 dilution) and secondary (1:800 dilution) antibodies as previously described 34 . Where noted cells were pre-extracted first with CSK buffer (10 mM PIPES at pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 1 mM EGTA, 0.5% Triton-X100) and cytoskeleton stripping buffer (10 mM Tris-HCl at pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 1% Tween 40 (v/v), 0.5% sodium deoxycholate (v/v)) followed by fixation with paraformaldehyde at 4%. Cells were blocked with 0.5% BSA, 0.2% gelatin in PBS ×1 and probed with respective primary and secondary antibodies. Labelled cells were viewed by epifluorescence microscopy. For immunohistochemistry deparaffinized 4 µm tissue sections were incubated in sodium citrate buffer (10 mM Na citrate, 0.05% Tween 20 at pH 6) at 95 • C for 45 min to retrieve antigens. Tissue sections were subsequently rinsed with water and incubated with block buffer (4% BSA in PBS +0.1% Tween 20, PBST) for 30 min. Primary antibodies were incubated overnight at 4 • C in block buffer (macroH2A 1:5,000; Ago2 1:200). Following 2 × 5 min washes with PBST, tissue sections were incubated with secondary antibodies as indicated (1:1,000 in block buffer) for 1 h at room temperature. Slides were washed (3 × 5 min) with PBST, rinsed with water and mounted using DAPI-containing mounting medium. Archival and paraffin-embedded tumour tissue were obtained from the tumour tissue bank at New Jersey Medical School University Hospital with the approval of the local institutional review board committee.
Transfection, reporter assays, siRNA, miRNA and antagomir. Cells were co-transfected with 0.1 µg wild-type or mutant cyclin E-luciferase 26 or CDC2 promoter-reporter constructs and mammalian expression vectors for pCMV-β-Gal (10 ng), pCMV-RB1 (300 ng), pCMV-E2F1/DP1 (10 ng), let-7 (100 nM) and pCMV-AGO1 and 2 at the indicated amounts in nanograms using Lipofectamine 2000 (Invitrogen). β-galactosidase and luciferase activities were measured using GalactoStar (Tropix) and luciferase (Promega) luminescent assay kits according to the suppliers' instructions. Luciferase activities were normalized with β-galactosidase activities. Expression of proteins was confirmed by Western blot (data not shown). For siRNA, miRNA and antagomir transfection experiments, cells were transfected at 100 nM. All siRNA duplexes were SMARTpools (Dharmacon). Pre-miR-let-7f, miR-let-7f and miR-let-7f antagomir were purchased from Exiqon. Respective scrambled sequences were used as negative control.
RNA isolation, qrtPCR analysis and qChIP-primers. Total RNA and cDNA preparation were carried out by standard procedures. Real-time PCR was conducted using Qiagen QuantiTec primer pairs and designed primer pairs for indicated genes or promoter-specific primers for qChIP analysis and nuclear-run-on assay (Supplementary Table S6 ) with Roche LightCycler and Roche Absolute QPCR SYBR Green Capillary Mixes. In all assays CYP served as normalization control.
RNA immunoprecipitation (RIP). Senescent cells induced by oncogenic RAS or
replicative exhaustion were crosslinked by ultraviolet radiation at 100-400 mJ cm −2 and immediately collected afterwards on ice. Cell pellets were lysed in radioimmunoprecipitation assay lysis buffer on ice, adjusted to a protein concentration of 10 mg ml −1 and digested extensively with DNase I for 15 min at 37 • Cfollowed by digestion with RNase T1 (1000 U ml −1 ) for 15 min at 23 • C. Lysates were cleared and incubated with 2 µg of pan-anti-AGO, anti-H3K9me2 or IgG-antibodies (Upstate). Immunoprecipitates were collected with protein A/G beads, washed extensively and incubated again with 5,000 U ml −1 RNase T1 at 23 • C to rid the precipitates of any unspecifically attached RNA molecules. Immunocomplexes were proteinase K-digested and purified RNA molecules ethanol-precipitated and used as probes in downstream applications.
Next-generation sequencing of small RNAs and analysis of sequencing data.
Small RNA samples were prepared from RIPs or unfractionated, cellular RNA of senescent cells using a Small RNA-Seq Sample Prep Kit (Illumina) followed by the standard Illumina RNA sequencing protocol using the Genome Analyser. Bioinformatic analysis of RNA-Seq results was carried out by GenomeQuest France (www.genomequest.com). Beginning with raw reads obtained from Illumina G1 sequencing the adaptor sequence was removed. All reads smaller than 18 nucleotides after removing the adaptor sequence were discarded, allowing one mismatch within the adaptor sequence. Small RNA sequences were mapped to the complete, unmasked, National Center for Biotechnology Information version of the human genome (build 36). The alignment algorithm used aligns the entire read, allowing one mismatch, insertion or deletion. Each sequence read was classified as either hit or no hit and was annotated with the number of hits found. All reads mapping to a single contiguous position in the genome were then clustered. For each genomic cluster the genomic sequence was extracted and put into a separate sequence database (the genomic cluster database). The cluster database was mapped to miRBase (v12, http://www.mirbase.org/), resulting in an miRNA annotated cluster database. miRNA reads were normalized to one million small RNAs (cpm). All mappings used the GenomeQuest KERR proprietary implementation. The KERR algorithm belongs to a class of approximate string-matching algorithms. Given two sequences S1 and S2, KERR computes the minimal number of differences between S1 and S2, by trying to optimally fit the shorter sequence into the longer one. Differences in sequence alignments arise from mismatches or gaps. This strategy assures finding all the local alignments allowing a given number of mismatches, insertions or deletions. For all comparisons one error was allowed. For more information about the GenomeQuest KERR implementation, please refer to http:// wiki.genomequest.com/index.php/LSPMUL_HELP#KERR_.28aka_GenePAST.29. ChiP-on-chip assay and bioinformatic analysis. We used a NimbleGen 385K
Promoter two-array set (UCSC HG18), which consists of 59,357 human promoters (see also www.nimblegen.com for details concerning array platform). Preparation of ChIP samples was per supplier's instructions. The labelling and hybridization of DNA from input and immunoprecipitation fractions for ChIP-on-chip analysis were carried out by NimbleGen Systems. Raw fluorescence-intensity data were obtained from scanned images of the oligonucleotide tiling arrays using NimbleScan 2.2 extraction software (NimbleGen Systems). Only peak data with a false-discoveryrate score of 0.05 or less were used for analysis. Scaled log 2-ratio data were viewed using SignalMap. Assembly of top E2F-target genes was from refs [8] [9] [10] [11] Accession numbers. The ChIP-on-chip data used in this study may be viewed under GSE33998 at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE33998.
The data from the genome-wide expression analysis used in this study may be viewed under GSE33710 at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE33710.
The RIP-Seq data used in this study may be viewed under GSE34494 at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE34494. Figure S2 a, Functional annotation clustering of AGO-bound E2F target genes downregulated in senescence. AGO-binding to downregulated E2F targets shows predilection for cell cycle control genes (colored in blue). Enrichment score is 21,04 and p-value < 0,01 using DAVID gene ontology tool (see also Supplementary Information, Table S2 ). b, Experimental design for small RNA sequence aquisition using Next-Generation Sequencing (NextGeneration-Seq) and bioinformatic analysis; RIP, RNA immunoprecipitation. Rel. AGO2 Expression a.
Figure S7 a, Expression profile of let-7 family members. Total RNA was prepared from Ras V12 -induced senescent and pre-senescent, control WI38 fibroblasts and hybridised to microarray as described in experimental procedures. b, MiR-let-7 corepresses the E2F-responsive CDC2 promoterreporter gene together with AGO2 and Rb. b, CDC2 promoter-luciferase reporter assays were performed in C33A cells using either a wild-type version of the CDC2 promoter or a derivative there-of in which the putative let-7 site is deleted. Promoter-reporter was stimulated by 10ng of E2F1/DP1 expression. Rb was used at 300ng, AGO2 at 100ng and let-7 at 100nM. Data are means ± s.d.; n=3; P < 0,05. Experiments were performed in triplicates. Expression of proteins was confirmed by Western blot (data not shown). c, Genomic locus of the human CDC2 gene and its upstream promoter fragment used in this study. Figure S8 AGO2 and pre-miR-let-7f induce TGS of E2F target promoters. Exogenous pre-miR-let-7f or control pre-miR (C) was transiently transfected at 100nM into pre-senescent WI38 fibroblasts. a, Abundance of CDCA8 and CDC2 mRNAs was measured by qRT-PCR of total RNA prepared from the respective samples. Data are means ± s.d.; n=3; P < 0,05. Experiments were performed in quadruplicates. b, qChIP was performed in pre-miR-let7f-treated cells using anti-AGO2 and anti-H3K27 me3 antibodies followed by qPCR using primers amplifying CDCA8 and CDC2 promoter regions. Data are means ± s.d.; n=3; P < 0,05. Experiments were performed in quadruplicates. c, Simultaneous presence of miR-185 and AGO2 on ORC6L promoter was determined by combined qChIP-ChOP assay. Biotin-labeled miR-185 (100nM) was transfected into pre-senescent WI38 fibroblasts followed by successive rounds of AGO2-ChIP or control-ChIP and streptavidin-affinity (SA) precipitation. SA-chromatin-precipitates were analyzed by qPCR with primers detecting E2F-responsive promoter ORC6L. Experiment was performed in quadruplicates and the s.d. is indicated. Also shown is the alignment of miR-185 to ORC6L target promoter. Identical nucleotides are shown in red.
Asterisk, transcription start site (TSS); E2F-binding site is depicted as grey box with respect to TSS ; Arrows to the right and left of miR-target are primers used for qChIP or qRT-PCR; numbers on top of indicate miR target site position with respect to TSS. d, Biotin-labeled let-7f (100nM) was transfected into pre-senescent WI38 fibroblasts followed by streptavidin-affinity (SA) precipitation. SA-chromatin-precipitates were analyzed by qPCR with primers detecting E2F-responsive promoters CDCA8 and CDC6. Data are means ± s.d.; n=3; P < 0,05. Experiments were performed in duplicates. (e-f), Exogenous pre-miR-let-7f induces cellular senescence. Pre-senescent WI38 fibroblasts were transiently transfected with 100nM pre-miR-let-7f, control pre-miR (C) or siCDCA8 and cell proliferation was determined at the indicated time points. Experiments were performed in duplicates. e, Growth curve and f, Number of cells staining positive for Ki67 and senescence-associated beta-galactosidase (SA-b-Gal) at day 7 post-treatment. Data are means ± s.d.; n=3; P < 0,05. Experiments were performed in duplicates. g, Cell number of pre-senescent WI38 fibroblasts 96 hrs after cotransfection with indicated siC, siAGO2 and let-7 combinations. Shown is the mean of quadruplicates. 
